Caris Life Sciences Authorized Buy Back Up To $100 Mln
(RTTNews) - Caris Life Sciences (CAI), an AI TechBio company, Monday announced that it has been authorized to repurchase up to $100 million of the company's outstanding common stock.
The timing, manner, price, and amount of any repurchases will be determined at the Company's discretion based on a variety of factors, including market conditions, the trading price of the Company's common stock, the Company's financial condition and results of operations, capital requirements, general business conditions, alternative investment opportunities, and other factors the Company deems relevant, the biotech form said.
In pre-market activity, CAI shares were trading at $16.67, up 1.09% on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.